Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model.
Bull Exp Biol Med
; 166(6): 739-743, 2019 Apr.
Article
de En
| MEDLINE
| ID: mdl-31020587
ABSTRACT
Activities of noncompetitive NMDA receptor antagonists (aminoadamantane derivatives) were assessed in random-bred rats with modeled morphine withdrawal syndrome. A single intraperitoneal injection of hemantane (10 or 20 mg/kg) significantly and dose-dependently moderated some behavioral symptoms (teeth-chattering, ptosis, and vocalization) and reduced total score of morphine withdrawal syndrome. In morphine-abstinent rats, hemantane partially prevented the decrease in the thresholds of tactile sensitivity, but had no effect on locomotor activity and body weight loss. Under conditions of morphine withdrawal, intraperitoneal injection of amantadine (10 or 20 mg/kg) decreased motor activity and promoted body weight loss in parallel with the development of mechanical allodynia, but had no effect on the total withdrawal score. Comparison of aminoadamantane derivatives by behavioral and physiological parameters demonstrated the advantage of hemantane during morphine abstinence indicating the need of its study as a promising anti-addiction remedy.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Syndrome de sevrage
/
Adamantane
/
Amantadine
/
Récepteurs du N-méthyl-D-aspartate
/
Dépendance à la morphine
/
Antagonistes narcotiques
Type d'étude:
Prognostic_studies
Limites:
Animals
Langue:
En
Journal:
Bull Exp Biol Med
Année:
2019
Type de document:
Article
Pays d'affiliation:
Russie